Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
- Maurie Markman
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Optimal chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas remains undefined. Despite this fact, the selection of a cytotoxic anti-neoplastic drug regimen for an individual patient with this rare malignancy may substantially impact both short-term symptomatic improvement and overall quality-of-life, which includes the toxicity of therapy.
Patients and methods
Two women with metastatic uterine carcinosarcomas recently treated at the Cleveland Clinic received therapy (carboplatin/paclitaxel) directly aimed at the “adenocarcinoma” component of their mixed endometrial cancers.
Both patients achieved substantial short-term objective and subjective improvement in cancer-related signs and symptoms, while experiencing limited treatment-associated toxicities.
This limited experience, and additional available data, suggest it is rational to initially treat patients with recurrent/metastatic uterine carcinosarcomas with anti-neoplastic drug strategies currently employed in the management of endometrial adenocarcinomas.
- Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Journal of Cancer Research and Clinical Oncology
Volume 130, Issue 11 , pp 645-648
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Uterine carcinosarcoma
- Industry Sectors
- Maurie Markman (1)
- Author Affiliations
- 1. University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, (Mail Box # 121), Houston, Texas, 77030, USA